NR4A1 and breast cancer: Despite the demonstrated efficacy of anti-hormonal treatment in patients with hormone receptor-positive (HR+) breast cancer (BC), intrinsic and acquired endocrine resistance occurs in a significant proportion of patients, leaving this tumor being still one of the most common causes of cancer-related death in women [1, 2].